Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification - Fig 4

(A) Kaplan-Meier curves for biochemical progression-free survival of all patients stratified according to D’Amico risk grouping: low vs. intermediate. (B) Kaplan-Meier curves for biochemical progression-free survival of two intermediate risk groups: patient with Gleason score (GS) ≤ 6 and pretreatment blood prostate-specific (PSA) levels > 10 ng.ml vs. patients with GS = 7 and any pretreatment PSA levels.